What does the future hold for cell-based tolerogenic therapy?
What does the future hold for cell-based tolerogenic therapy?
复制标题
DOI：
10.1038/nri2137
复制
发表时间：
2007-08-01
影响因子：
100.3
通讯作者：
Weiner, Howard L.
中科院分区：
文献类型：
--
作者：
Bluestone, Jeffrey A.;Thomson, Angus W.;Weiner, Howard L.
来自动物模型的证据表明，调节性 T 细胞或耐受性树突状细胞的转移可以预防或治愈移植排斥或重建自身免疫性疾病的自我耐受性。近年来，这些致耐受性细胞治疗人类 T 细胞介导的疾病的潜力不断增强。在此，《自然评论免疫学》要求四位领先的研究人员提供他们对基于细胞的耐受性治疗的未来的看法，并强调在这种形式的免疫治疗成为现实之前必须考虑的一些重要问题。
Evidence from animal models has shown that the transfer of regulatory T cells or tolerogenic dendritic cells can prevent or cure transplant rejection or re-establish self-tolerance in autoimmune disease. The potential of these tolerogenic cells for the treatment of T-cell-mediated diseases in humans has gained momentum in recent years. Here, Nature Reviews Immunology asks four leading researchers to provide their view on the future of cell-based tolerogenic therapy and to highlight some important issues that must be considered before this form of immunotherapy can become a reality.